CinCor Pharma, Inc.

CINCNASDAQHealthcare

$29.06

+$0.00(+0.00%)

Market Cap$1.3B

P/E Ratio—

52W High$43.15

52W Low$10.53

Avg Volume619K

Open$29.17

Beta0.00

Forecast Market Cap PE Ratio

CinCor Pharma, Inc.（CINC）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

cinc · 股价预测 · 7 位分析师（近3月）· FMP · 更新于 2023年12月4日

分析师评级与共识

基于过去 3 个月内 7 位华尔街分析师

Buy

7 位分析师

共识

评级分布

Strong Buy

Buy

Hold

Sell

Strong Sell

合计: 7 · 买入占比: 57.1%

12 个月目标价

High

$73.00

Consensus

$48.50

+66.9% upside

Low

$30.00

Median: $45.5 · Last Close: $29.06

CinCor Pharma, Inc.（CINC）的分析师共识为 Buy，基于过去 3 个月内 7 位华尔街分析师的评级。CINC 的 12 个月平均目标价为 $48.50，相对当前价 $29.06 代表 +66.9% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

Historical priceConsensus $49 (66.9%)High $73Low $30

Consensus Target

$48.50

66.9% upside

High Target

$73

151.2%

Low Target

$30

3.2%

Current Price

$29.06

as of today

Based on analyst price targets, the CINC stock price prediction for the next 12 months ranges from $30 to $73. The consensus CINC price forecast of $48.50 implies 66.9% upside from the current price of $29.06.

短期股价预测

算法生成 · 每日更新

Date	Predicted Price	Change	Min	Max
2026-06-09	$29.09	↑ 0.11%	$29.07	$29.11

1-day model range: $29.07–$29.11. Peak: $29.11 (+0.11%).

长期股价预测

⚠️ 在满 252 个交易日历史（IPO/上市时间较短）前不展示长期预测；短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

NEUTRAL

Based on 14 technical indicators

0%57%43%

0Buy

8Neutral

6Sell

RSI (14)50.7Neutral

MACDNEUTRAL

Refreshes daily from EOD close

Moving Averages · CINC · Jun 9, 2026

Simple Moving Average (SMA)

MA 5$29.22SELL

MA 10$29.32SELL

MA 20$29.18SELL

MA 50$0.00NEUTRAL

MA 100$0.00NEUTRAL

MA 200$0.00NEUTRAL

Current $CINC · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$29.20SELL

EMA 10$29.24SELL

EMA 20$29.17SELL

EMA 50$0.00NEUTRAL

EMA 100$0.00NEUTRAL

EMA 200$0.00NEUTRAL

Current $CINC · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:

Date	Brokerage	Action	Rating
2023-01-12	Barclays	Downgrade ↓	Overweight→Equal Weight
2023-01-10	Morgan Stanley	Maintains	Equal Weight→Equal Weight
2022-12-08	Barclays	Maintains	Overweight→Overweight
2022-12-07	Barclays	Maintains	Overweight→Overweight
2022-11-29	Oppenheimer	Downgrade ↓	Outperform→Perform
2022-11-29	Morgan Stanley	Downgrade ↓	Overweight→Equal Weight
2022-10-28	Goldman Sachs	Maintains	Buy→Buy
2022-09-09	Morgan Stanley	Maintains	Overweight→Overweight
2022-08-22	Piper Sandler	Maintains	Overweight→Overweight
2022-08-09	Morgan Stanley	Maintains	Overweight→Overweight

Barclays2023-01-12

Downgrade ↓

Overweight→Equal Weight

Morgan Stanley2023-01-10

Maintains

Equal Weight→Equal Weight

Barclays2022-12-08

Maintains

Overweight→Overweight

Barclays2022-12-07

Maintains

Overweight→Overweight

Oppenheimer2022-11-29

Downgrade ↓

Outperform→Perform

Morgan Stanley2022-11-29

Downgrade ↓

Overweight→Equal Weight

Goldman Sachs2022-10-28

Maintains

Buy→Buy

Morgan Stanley2022-09-09

Maintains

Overweight→Overweight

Piper Sandler2022-08-22

Maintains

Overweight→Overweight

Morgan Stanley2022-08-09

Maintains

Overweight→Overweight

Wall Street analysts have recently issued updated ratings on CinCor Pharma, Inc. (CINC) stock. Of the recent 16 rating actions, 0 were upgrades and 3 were downgrades. 7 analysts currently cover CINC.

分析师推荐趋势

Buy ratings2 → 0↓ 2

Hold ratings0 → 2↑ +2

Sell ratings0 → 0

CINC analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

—

Revenue Next Year

—

EPS This Year

—

EPS Next Year

—

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast CINC EPS of $— for the current fiscal year, based on estimates from 0 analysts. The CINC revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

CINC 股价预测由两类独立数据源支撑：来自 7 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。CINC 的共识目标价为 $48.50（+66.9% 上行空间），分析师共识为 Buy。

CINC 的短期预测（明日）为 $29.09（+0.11%）。

CinCor Pharma, Inc. 在 NASDAQ 上市，代码 CINC。CINC 在 2027 年的整体展望偏积极，在覆盖分析师中约 57% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

CINC 预测 · 8 个问题

根据 7 位华尔街分析师，CINC 的 12 个月平均目标价为 $48.50，最高 $73.00、最低 $30.00。若有图表，中位目标价可在上方查看。相对当前价 $29.06，隐含约 +66.9% 的上行空间。

CINC 目标价CINC 分析师目标价CINC 12个月目标价目标价 CINC

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.